The estimated Net Worth of Thomas Andrew Davis is at least $754 mil dollars as of 4 April 2022. Thomas Davis owns over 1,091 units of Genocea Biosciences Inc stock worth over $0 and over the last 16 years he sold GNCA stock worth over $4,352. In addition, he makes $749,658 as Chief Medical Officer at Genocea Biosciences Inc.
Thomas has made over 3 trades of the Genocea Biosciences Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 1,091 units of GNCA stock worth $1,364 on 4 April 2022.
The largest trade he's ever made was selling 2,717 units of Genocea Biosciences Inc stock on 15 March 2022 worth over $2,989. On average, Thomas trades about 371 units every 248 days since 2009. As of 4 April 2022 he still owns at least 68,330 units of Genocea Biosciences Inc stock.
You can see the complete history of Thomas Davis stock trades at the bottom of the page.
Dr. Thomas Andrew Davis M.D. serves as Chief Medical Officer of the Company. Dr. Tom joined Genocea in October 2018 as Chief Medical Officer with over 20 years of academic and industry experience in immuno-oncology and cancer drug development. Most recently, he served as Chief Medical Officer of Gadeta B.V., a Dutch cell therapy company pursuing novel cancer targets from October 2017 to April 2018, where he steered a novel cell therapy technology into first-in human clinical studies. Prior to Gadeta B.V., he served as Chief Medical Officer of Celldex from 2006 to 2017, where he led all aspects of clinical and regulatory development including strategy, tactics, and execution. While at Celldex, Tom actively built and oversaw Clinical Science, Medical Affairs, Safety, Clinical Operations, Statistics, Regulatory Affairs, and Project Management, managed collaborations with large global pharmaceutical partners, and participated in investor relations activities. He also served as Chief Medical Officer at GenVec and as Senior Director of Clinical Science at Medarex.Prior to joining the industry, Tom supervised clinical efforts at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), and worked on the development of rituximab and idiotype vaccines at Stanford University. Dr. Davis received his B.A. in Biophysics from Johns Hopkins, his M.S. in Physiology and his M.D. from Georgetown University, and completed a fellowship in medical oncology at Stanford University.
As the Chief Medical Officer of Genocea Biosciences Inc, the total compensation of Thomas Davis at Genocea Biosciences Inc is $749,658. There are 3 executives at Genocea Biosciences Inc getting paid more, with William Clark having the highest compensation of $1,063,000.
Thomas Davis is 56, he's been the Chief Medical Officer of Genocea Biosciences Inc since 2018. There are 6 older and 12 younger executives at Genocea Biosciences Inc. The oldest executive at Genocea Biosciences Inc is George Siber, 75, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE, MA, 02140.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: